CytomX Therapeutics Inc [NASDAQ: CTMX] gained 4.42% or 0.11 points to close at $2.6 with a heavy trading volume of 3708809 shares.
It opened the trading session at $2.5, the shares rose to $2.79 and dropped to $2.44, the range by which the price of stock traded the whole day. The daily chart for CTMX points out that the company has recorded 128.07% gains over the past six months.
If we look at the average trading volume of 5.17M shares, CTMX reached to a volume of 3708809 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about CytomX Therapeutics Inc [CTMX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTMX shares is $5.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTMX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for CytomX Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 15, 2025. While these analysts kept the previous recommendation, Piper Sandler dropped their target price from $3.25 to $2.50. The new note on the price target was released on April 14, 2025, representing the official price target for CytomX Therapeutics Inc stock. Previously, the target price had yet another raise from $2.25 to $3.50, while Piper Sandler kept a Overweight rating on CTMX stock.
The Price to Book ratio for the last quarter was 8.37, with the Price to Cash per share for the same quarter was set at 0.51.
Trading performance analysis for CTMX stock
CytomX Therapeutics Inc [CTMX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.84. With this latest performance, CTMX shares dropped by -1.33% in over the last four-week period, additionally plugging by 128.07% over the last 6 months – not to mention a rise of 152.43% in the past year of trading.
CytomX Therapeutics Inc [CTMX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and CytomX Therapeutics Inc [CTMX] shares currently have an operating margin of 24.37% and a Gross Margin at 98.86%. CytomX Therapeutics Inc’s Net Margin is presently recorded at 28.19%.
Return on Equity for this stock inclined to 29.38%, with Return on Assets sitting at 29.38%.
An analysis of Institutional ownership at CytomX Therapeutics Inc [CTMX]
There are presently around $51.02%, or 51.44% of CTMX stock, in the hands of institutional investors. The top three institutional holders of CTMX stocks are: TANG CAPITAL MANAGEMENT LLC with ownership of 7.79 million shares, which is approximately 9.1799%. JANUS HENDERSON GROUP PLC, holding 6.3 million shares of the stock with an approximate value of $$7.72 million in CTMX stocks shares; and JANUS HENDERSON GROUP PLC, currently with $$6.38 million in CTMX stock with ownership which is approximately 6.1598%.
